Division of Hematology and Clinical Pharmacy, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada.
Transfusion. 2012 Apr;52(4):739-41. doi: 10.1111/j.1537-2995.2011.03382.x. Epub 2011 Nov 14.
Refractoriness to platelet (PLT) transfusion is a feared, life-threatening complication in hematology-oncology patients. Despite increased PLT requirement and treatment costs, the clinical management is difficult and these patients had less favorable outcomes.
We report on the efficacy of the thrombopoietic agent romiplostim in a patient with acute myeloid leukemia with chemotherapy-induced transfusion-refractory thrombocytopenia.
Romiplostim could be very helpfull in the management of AML patients with transfusion refractory thrombocytopenia.
血小板（PLT）输注抵抗是血液科-肿瘤学患者中一种令人畏惧的、危及生命的并发症。尽管 PLT 需求增加和治疗费用增加，但临床管理困难，这些患者的预后较差。
我们报告了促血小板生成素激动剂罗米司亭在一名因化疗引起的输血难治性血小板减少症的急性髓系白血病患者中的疗效。
罗米司亭在治疗输血难治性血小板减少症的 AML 患者方面可能非常有帮助。
